Clinical Trial: Safety and Immunogenicity of a Vi-DT Typhoid Conjugate Vaccine

Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Interventional




Official Title: A Randomized, Observer-Blinded, Phase I Study to Assess the Safety and Immunogenicity of Vi-DT Conjugate Vaccine Compared to Vi-Polysaccharide (Typhim Vi®, Sanofi Pasteur) Typhoid Vaccine in Heal

Brief Summary:

This is a Phase I, Randomized, observer-blinded, age de-escalating study.

The study objectives are

to evaluate the safety of 25 μg of Vi-DT typhoid conjugate vaccine administered at 0 and 4 weeks.

to assess the immunogenicity of 25 μg of Vi-DT typhoid conjugate vaccine administered at 0 and 4 weeks.

to compare the safety and immunogenicity of Vi-DT and Vi-Polysaccharide typhoid vaccines.